

## PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1  
 Stylesheet Version v1.2

EPAS ID: PAT3868556

|   |                                  |                       |  |
|---|----------------------------------|-----------------------|--|
| <b>SUBMISSION TYPE:</b>   | NEW ASSIGNMENT                   |                       |  |
| <b>NATURE OF CONVEYANCE:</b>  | ASSIGNMENT                       |                       |  |
| <b>SEQUENCE:</b>  | 3                                |                       |  |
| <b>CONVEYING PARTY DATA</b>   |                                  |                       |  |
| <b>Name</b>   |                                  | <b>Execution Date</b> |  |
| CHARLES DAVID ADAIR M.D.  |                                  | 04/10/2008            |  |
| <b>RECEIVING PARTY DATA</b>   |                                  |                       |  |
| <b>Name:</b>  | GLENVEIGH PHARMACEUTICALS, LLC   |                       |  |
| <b>Street Address:</b>  | 401 CHESTNUT STREET              |                       |  |
| <b>Internal Address:</b>  | SUITE 230                        |                       |  |
| <b>City:</b>  | CHATTANOOGA                      |                       |  |
| <b>State/Country:</b>   | TENNESSEE                        |                       |  |
| <b>Postal Code:</b>   | 37403                            |                       |  |
| <b>PROPERTY NUMBERS Total: 2</b>  |                                  |                       |  |
| <b>Property Type</b>  | <b>Number</b>                    |                       |  |
| <b>Application Number:</b>  | 13372151                         |                       |  |
| <b>Application Number:</b>  | 12849651                         |                       |  |
| <b>CORRESPONDENCE DATA</b>  |                                  |                       |  |
| <b>Fax Number:</b>  | (202)778-2201                    |                       |  |
| <i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i> |                                  |                       |  |
| <b>Phone:</b>   | 202-955-1500                     |                       |  |
| <b>Email:</b>   | ccurrie@hunton.com               |                       |  |
| <b>Correspondent Name:</b>  | HUNTON & WILLIAMS LLP            |                       |  |
| <b>Address Line 1:</b>  | 2200 PENNSYLVANIA AVENUE, N.W.   |                       |  |
| <b>Address Line 2:</b>  | INTELLECTUAL PROPERTY DEPARTMENT |                       |  |
| <b>Address Line 4:</b>  | WASHINGTON, D.C. 20037-1701      |                       |  |
| <b>ATTORNEY DOCKET NUMBER:</b>  | 78690.000207                     |                       |  |
| <b>NAME OF SUBMITTER:</b>   | CHRISTOPHER J. NICHOLS           |                       |  |
| <b>SIGNATURE:</b>   | /CHRISTOPHER J. NICHOLS/         |                       |  |
| <b>DATE SIGNED:</b>   | 05/11/2016                       |                       |  |
| <b>Total Attachments: 4</b>   |                                  |                       |  |
| source=Assn3ADAIrtoGLENVEIGHAssignment2008-04-10#page1.tif  |                                  |                       |  |
| source=Assn3ADAIrtoGLENVEIGHAssignment2008-04-10#page2.tif  |                                  |                       |  |

source=Assn3ADAIrtoGLENVEIGHAssignment2008-04-10#page3.tif

source=Assn3ADAIrtoGLENVEIGHAssignment2008-04-10#page4.tif

**PATENT**

**REEL: 038550 FRAME: 0536**

### ASSIGNMENT

THIS ASSIGNMENT (the "Assignment") is made by and between Charles David Adair, M.D., an individual residing in Signal Mountain, Tennessee, USA (hereinafter referred to as "DR. ADAIR"), and Glenveigh Pharmaceuticals, LLC, a Delaware limited liability company (hereinafter referred to as "ASSIGNEE").

### WITNESSETH

WHEREAS, DR. ADAIR has conceived a new and useful treatment for preeclampsia and eclampsia in human patients, for which DR. ADAIR is the sole inventor, and has filed that certain Patent Application titled **"Method for Controlling Preeclampsia and Eclampsia"** (Serial No. 10/202,957) (the "Original Application") for Letters Patent in the United States of America, such invention being described and identified by said Original Application; and

WHEREAS, DR. ADAIR has filed a continuation United States Patent Application claiming priority under the Original Application, titled **"Use of Digoxin Immune Fab (Ovine) for the Regulation of Sodium/Potassium ATPase Activity in Preeclamptic and Eclamptic Patients"** (Serial No. 10/292,338) for Letters Patent in the United States of America, such invention being described and identified by said application (the "First Continuation Application"), a provisional United States Patent Application, titled **"Method to Prevent or Treat Pregnancy-Induced Hypertension and Intrauterine Growth Restriction"** (Serial No.60/681,693) ("Provisional Application"), a second continuation United States Patent Application claiming priority under the Original Application, the First Continuation Application and the Provisional Application, titled **"Antibody Compositions and Passive Immunization Against Pregnancy-Induced Hypertension"** (Serial No. 11/317,378) (the "Second Continuation Application"), and has filed certain international patent applications based upon the foregoing, namely **"Use of Digoxin Immune Fab (Ovine) for the Regulation of Sodium/Potassium ATPase Activity in Preeclamptic and Eclamptic Patients"** (Application No. PCT/US03/23235) (the "First PCT Application"), and **"Antibody Compositions and Passive Immunization Against Pregnancy-Induced Hypertension"** (Application No. PCT/US06/018876) (the "Second PCT Application"); collectively, the foregoing patent applications are referred to herein as the "Patent Applications" and the inventions described in the Patent Applications are referred to herein as the "Inventions"; and

WHEREAS, DR. ADAIR has previously sold and granted to CDA ROYALTY INVESTORS, LLC an aggregate twelve and 43/100's percent (12.43%) undivided interest in and to said Inventions and any Letters Patents granted thereon by the United States of America or other instruments granted by any foreign country with respect to any patent applications claiming priority under any one or more of the Original Application, the First or Second Continuation Applications or the First or Second PCT Applications, pursuant to that certain ASSIGNMENT NUNC PRO TUNC recorded with the USPTO on or about January 3, 2007 and that certain ASSIGNMENT NUNC PRO TUNC being recorded with the USPTO contemporaneously herewith; and

WHEREAS, DR. ADAIR desires to assign to ASSIGNEE all of his remaining interests in and to said Inventions and any Letters Patents granted thereon by the United States of America or other instruments granted by any foreign country with respect to any patent applications claiming

priority under any one or more of the Original Application, the First or Second Continuation Applications or the First or Second PCT Applications.

NOW, THEREFORE, in consideration of the sum of One Dollar (\$1.00) and for other good and valuable consideration received by DR. ADAIR from ASSIGNEE, the receipt and sufficiency of which are hereby acknowledged, the parties agree as follows:

1. ASSIGNMENT OF UNDIVIDED INTERESTS. DR. ADAIR hereby sells, assigns, transfers and conveys unto ASSIGNEE and ASSIGNEE hereby accepts, effective as of February 1, 2008, all of his undivided interest (87.57%) (the "Undivided Interest") of the rights and title in and to said Inventions, the Patent Applications therefore identified on **Schedule A**, which is attached hereto and incorporated herein by this reference, together with all U.S. or foreign patent applications filed after the date hereof which claim priority solely under any one or more of the Patent Applications, and any Letters Patent or other patent rights or instruments granted or issued thereon by the United States of America, or any foreign country, or by any union or affiliation of countries, including any re-examination, reissue or extension thereof, and covenants that he has the full right to do so.

3. DIRECTIONS TO PATENT OFFICES. DR. ADAIR hereby authorizes and requests the DIRECTOR OF PATENTS OF THE UNITED STATES PATENT AND TRADEMARK OFFICE and the DIRECTOR, COMMISSIONER or other officer of every foreign country or of any union or association of countries to issue the Letters Patent or other patent documents and instruments evidencing patent rights in or to said Inventions and Patent Applications, when granted, to CDA ROYALTY INVESTORS, LLC and ASSIGNEE as joint owners of an undivided interest therein.

4. MISCELLANEOUS. This assignment shall be binding upon and inure to the benefit of DR. ADAIR and ASSIGNEE, their respective heirs, successors, permitted assigns and other legal representatives. This Agreement shall be governed by the laws of the State of Tennessee, excluding its conflicts-of-law principles.

[SIGNATURES ON FOLLOWING PAGE]

IN TESTIMONY WHEREOF, DR. ADAIR and ASSIGNEE have executed this Assignment as of and effective April 10, 2008.

C. David Adair  
Charles David Adair  
114 Cunningham Lane  
Signal Mountain, TN 37377

Glenveigh Pharmaceuticals, LLC

C. David Adair  
By: C. David Adair  
Its: Chairman


Address: 979 E. 3rd St.  
Suite C825, Chattanooga, TN  
37403

STATE OF TENNESSEE )  
 ) ss.  
COUNTY OF HAMILTON )

Before me, a Notary Public, of the state and county aforesaid, on this 10 day of April, 2008, personally appeared CHARLES DAVID ADAIR, with whom I am personally acquainted (or proved to me on the basis of satisfactory evidence), and who, upon oath, acknowledged himself to be the within named bargainor, and that he executed the foregoing instrument for the purpose therein contained as his voluntary act and deed.

WITNESS my hand and seal in the City of Chattanooga, Hamilton County, Tennessee, on this 10th day of April, 2008.

Freda Miller  
Notary Public  
My Commission Expires January 18, 2012 [SEAL]




STATE OF TENNESSEE )  
 ) ss.  
COUNTY OF HAMILTON )

Before me, a Notary Public, of the state and county aforesaid, on this 10th day of April, 2008, personally appeared C. David Adair, with whom I am personally acquainted (or proved to me on the basis of satisfactory evidence), and who, upon oath, acknowledged himself to be the Chairman of GLENVEIGH PHARMACEUTICALS, LLC, (the "Company"), the within named bargainor, and that he executed the foregoing instrument for the purpose therein contained with the authority of and on behalf of the Company.

WITNESS my hand and seal in the City of Chattanooga, Hamilton County, Tennessee, on this 10th day of April, 2008.

Freda Miller  
Notary Public  
My Commission Expires January 18, 2012 [SEAL]



FACHATTANO52827.03

3

PATENT  
REEL: 022548 FRAME: 0718

PATENT  
REEL: 038550 FRAME: 0539

**SCHEDULE A**  
**TO**  
**ASSIGNMENT**

| INVENTION TITLE  | COUNTRY       | INVENTOR(S)    | FILING DATE       | SERIAL NO./<br>APPLICATION<br>NO. |
|--|---------------|----------------|-------------------|-----------------------------------|
| Method of Controlling<br>Preeclampsia or Eclampsia   | United States | C. David Adair | July 25, 2002     | 10/202,957                        |
| Use of Digoxin Immune<br>Fab (Ovine) for the<br>Regulation of<br>Sodium/Potassium ATPase<br>Activity in Preeclamptic<br>and Eclamptic Patients | United States | C. David Adair | November 12, 2002 | 10/292,338                        |
| Method to Prevent or Treat<br>Pregnancy- Induced<br>Hypertension and<br>Intrauterine Growth<br>Restriction<br>(Provisional Application)        | United States | C. David Adair | May 17, 2005      | 60/681,693                        |
| Antibody Compositions and<br>Passive Immunization<br>Against Pregnancy-Induced<br>Hypertension   | United States | C. David Adair | December 23, 2005 | 11/317,378                        |
| Use of Digoxin Immune<br>Fab (Ovine) for the<br>Regulation of<br>Sodium/Potassium ATPase<br>Activity in Preeclamptic<br>and Eclamptic Patients | International | C. David Adair | July 23, 2003     | PCT/US03/23235                    |
| Antibody Compositions and<br>Passive Immunization<br>Against Pregnancy-Induced<br>Hypertension   | International | C. David Adair | May 17, 2006      | PCT/US06/018876                   |

FACHATTANOS2827.03

4

**RECORDED: 04/15/2009**

**PATENT**  
**REEL: 022548 FRAME: 0719**

**RECORDED: 05/11/2016**

**PATENT**  
**REEL: 038550 FRAME: 0540**